On March 04, Immutep Ltd. (IMMP) gained 6.18% during the regular session only to lose 6.91% in the after-hours. There is no recent official announcement or SEC filing while the company has three conferences enlisted for March in its schedule.
During the regular trading session, the stock varied between a range of $2.4701 and $2.8000. At an above-average volume of 319.73K shares, IMMP stock remained in the green during the session as it added $0.16 or 6.18%. At the close of the session, the stock had a price of $2.7500 per share. Following this, the stock reversed its gains as it plunged down to $2.5600 in the after hours.
The biotechnology company, Immutep Ltd. focuses on cancer and autoimmune diseases treatment development. Currently, the company has a market capitalization of $225.99 million with its 85.41 million outstanding shares.
IMMP’s Movement
IMMP stock had recently plunged down to its 52-week low of $2.02 on February 24, as the stock market saw a downtrend amid the escalating Russia-Ukraine conflict. Following this, the stock had been bullish from February 28 till March 3, when it fell prey to profit booking. The stock resumed its bullish course on March 04. But gaining some more during the regular session, the stock once again suffered a decline as it lost more than what is gained. Since there is no official announcement or SEC filing, the stock seems to be reacting to external factors. Thus, IMMP stock might be moving due to social media discussions or stock sentiment.
In the past five days, the stock has increased by 13.64% while it has declined by 16.16% year to date. Moreover, IMMP stock was able to add a value of 11.79% last year.
Upcoming Investor Conferences
The company will be participating in three upcoming investors conferences in March. Firstly, in the 42nd Annual Cowen Health Care Conference which will take place from March 7 to 9, 2022. The company will present as well as take part in 1-on-1 meetings during the conference. Secondly, in the Maxim Growth Conference which will be held from March 28 to 30, 2022. IMMP’s CEO Marc Voigt will deliver a corporate presentation along with participation in a fireside chat at the conference.
In addition, as announced on February 18, the company will be presenting new data from its TACTI-002 phase II trial at ESMO’s European Lung Cancer Congress (ELCC) 2022. The event will take place in person and virtually from March 20 to April 2, in Prague, Czech Republic.
